S&P 500 Consumer Staples Sector SEC Filings — March 20, 2026

20-03-2026

Wellgistics Health, Inc.'s 10-K filing describes its business operations across distribution, third-party logistics, and the DelivMeds digital pharmacy platform, supported by a network of over 5,000 pharmacies and facilities in Florida and Ohio. Acquisition-related consideration for Wellgistics LLC and Wood Sage includes $10M cash, $15M promissory note, and up to $25M in stock bonuses, with contingents tied to EBITDA targets through 2026. However, the filing emphasizes extensive risks including integration difficulties, reimbursement reductions, margin compression, and competitive pressures, with no financial performance metrics provided.

• ·Primary distribution center in Lakeland, Florida; additional facility in Columbus, Ohio; main office in Tampa, Florida.
• ·Contingent bonuses: 50% cash and 50% common stock if EBITDA exceeds 110% of targets for years ended Dec 31, 2024, 2025, and 2026.
• ·Promissory note interest: simple interest at Prime Rate as published by Wall Street Journal on Jan 1 of applicable year, payable in three equal annual installments starting first anniversary of registration effectiveness.
• ·Remainder of $10M cash due no later than earlier of 45 days post-registration effectiveness or Aug 30, 2025.

20-03-2026

Claritev Corporation (CTEV) filed a DEFA14A Definitive Additional Materials proxy statement with the SEC on March 20, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as definitive additional materials. No financial data, proposals, quantitative metrics, or period-over-period comparisons are included in the provided excerpt.

20-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 20, 2026, announcing a press release stating that its RAD division has booked an order for 5 RIO 360 units destined for the Downtown Civic Center in a major Midwest city. This development underscores demand for AITX's AI-driven security solutions amid otherwise limited financial details in the filing.

• ·Filing includes Exhibit 99.1: Press release dated March 20, 2026

20-03-2026

Belpointe PREP, LLC reported total assets of $564.2M as of Dec 31, 2025, up 9% YoY from $517.6M, driven by real estate net growth to $531.9M (+10% YoY), while revenue surged 244% YoY to $9.2M. However, net loss attributable to the company widened 68% YoY to $40.0M from $23.9M, with loss per Class A unit deteriorating to $(10.72) from $(6.56), amid higher debt ($260.6M, +47% YoY), elevated interest expense (+74% YoY), and negative NOI across Commercial (-$1.1M) and Mixed-use (-$1.3M) segments.

• ·Cash flows used in operating activities worsened to $(25.2M) in 2025 from $(13.7M) in 2024.
• ·Cash flows from financing activities declined to $87.0M in 2025 from $157.0M in 2024, leading to a net cash decrease of $0.2M.
• ·Commercial Segment NOI: $(1.1M) in 2025 vs $(0.05M) in 2024; Mixed-use Segment NOI: $(1.3M) in 2025 vs $(1.4M) in 2024 (slight improvement but still negative).

20-03-2026

Revenues and other income surged 61.7% YoY to $79.6M in 2025 from $49.2M in 2024, primarily driven by collaboration agreements rising to $72.1M (76.2% increase) and other revenues up 43.9% to $0.9M. However, net loss attributable to shareholders widened 83.9% to $67.6M from $36.8M, operating expenses increased with R&D up 3.3% to $93.5M and SG&A up 3.7% to $19.8M, cash and cash equivalents fell 19.8% to $208.7M, and shareholders' equity declined 42.1% to $75.9M.

• ·EPS basic and diluted FY2025: ($0.67), worsened from ($0.41) in FY2024.
• ·Total assets declined 15.4% to $324.7M as of Dec 31, 2025 from $383.5M.
• ·Adjusted Net Loss attributable to shareholders FY2025: $61.5M, vs $33.6M in FY2024.

20-03-2026

Pelican Acquisition Corp, a SPAC, reported net income of $1.25M for the year ended January 31, 2026, compared to a $42.6k loss in the prior inception-to-January 31, 2025 period, primarily driven by $2.35M in interest income from its newly funded $88.6M Trust Account holding 8,625,000 redeemable shares at $10.27 per share post-IPO. However, general and administrative expenses surged to $1.1M from $43k, leading to a $1.1M operational loss, while shareholders' deficit widened to $(405k) from $(13k). Total assets grew to $88.8M from $208k, reflecting IPO proceeds, but cash remained minimal at $77.

• ·Promissory note – related party: $0 at Jan 31, 2026 (down from $200k at Jan 31, 2025)
• ·Due to target company (Greenland): $100k as of Jan 31, 2026
• ·IPO-related: Private Placement Units issuance raised $2.99M; Public Rights net $1.34M
• ·Remeasurement of carrying value to redemption value: $(4.5M) and $(888k); Accretion $(792k)

20-03-2026

Primoris Services Corporation (NYSE: PRIM) has issued its 2026 Proxy Statement for the virtual Annual Meeting of Stockholders on April 30, 2026, at 9:00 a.m. CT, where shareholders will vote on electing eight directors, advisory approval of named executive officer compensation, and ratification of Baker Tilly US, LLP as independent auditors for the fiscal year ending December 31, 2026. The company describes 2025 as an exceptional year, achieving record milestones, accelerating strategic growth, generating strong cash flow, and strengthening its balance sheet. Chairman David L. King thanks retiring Board member John Schauerman for his long service.

• ·Record date for shareholders entitled to vote: March 9, 2026
• ·Virtual meeting registration deadline: April 24, 2026, 11:59 p.m. Central Time at www.proxydocs.com/PRIM
• ·Principal executive offices: 2300 N. Field Street, Suite 1900, Dallas, Texas 75201

20-03-2026

Yellowstone MidCo Holdings II, LLC reported revenue growth of 52% YoY to $386M for 2025 from $254M in 2024, with gross profit tripling to $75M (20% margin from 13%) and Adjusted EBITDA improving to -$8M from -$43M. However, the company posted a net loss of $85M (narrowed 15% YoY), operating expenses increased 17% driven by higher SG&A (+11%) and transaction costs, R&D declined 10%, and net cash used in operations was $121M versus provided by $32M prior year.

• ·Net EAC adjustments before taxes: -$11.1M in 2025 vs -$22.9M in 2024.
• ·Minimum revenue guarantees extend to Sep 2028 at $758M.
• ·Cash increased $58M to $163M end-2025, driven by $204M financing inflows.

20-03-2026

StimCell Energetics Inc. (OTCQB: STME) engaged Stonegate Capital Partners, Inc. for research coverage and institutional investor outreach under an Advisory Services Agreement effective March 12, 2026, with services including quarterly research updates and coordination of investor meetings for a 12-month term. Compensation consists of 250,000 shares of common stock issued to Stonegate. CEO David Jeffs highlighted the partnership's potential to elevate visibility and build institutional ownership for the company's eBalance® technology.

• ·Shares subject to a six-month hold period from issuance date.
• ·Shares issued pursuant to exemptions from prospectus requirements of Canadian securities laws and registration requirements of U.S. Securities Act of 1933.
• ·Company focuses on products enhancing cellular function for wellness, anti-aging, insulin sensitivity, high blood pressure, neuropathy, and kidney function.

20-03-2026

Ascend Wellness Holdings, Inc. issued a notice of availability of proxy materials for its virtual Annual Meeting of Stockholders on April 29, 2026, at 11:00 a.m. ET. Key proposals include election of directors, ratification of WithumSmith+Brown, PC as independent auditors, and approval of the stock incentive plan, all recommended 'FOR' by the Board. No financial metrics or performance data are disclosed in this filing.

• ·Paper copy requests deadline: April 15, 2026, 4:00 p.m. ET
• ·Proxy submission deadline: April 27, 2026, 11:00 a.m. ET
• ·Virtual meeting link: https://meetings.lumiconnect.com/400-906-287-553 (password: ascend2026)
• ·Proxy materials available at: https://odysseytrust.com/client/ascend-wellness-holdings/ or www.sedarplus.ca

20-03-2026

Intelligent Protection Management Corp. (IPM) furnished an investor presentation reporting Full Year 2025 revenue of $23.6M and Q4 2025 revenue of $6.1M, with net loss declining 42% YoY and Adjusted EBITDA turning positive in Q4, marking the first operational quarter post-transformation in Q1 2025. The company acquired Newtek Technology Solutions from NewtekOne in January 2025 for $4.0M cash and 4.0M shares of non-voting convertible preferred stock, adding over 50 employees and more than 17,000 customers, while divesting non-core legacy businesses for $1.4M plus up to $5M in earn-outs. No declines in revenue were reported, though historical net losses persist despite improvement.

• ·Q4 2025 Revenue Breakdown: Managed Information Technology $3.9M, Procurement $0.4M, Professional Services $1.5M, Subscription $0.3M
• ·Full Year 2025 Revenue Breakdown: Managed Information Technology $14.8M, Procurement $5.4M, Professional Services $1.1M, Subscription $2.3M
• ·Data center leases through 2032
• ·Historical gross margins of 50-55%

20-03-2026

On March 18, 2026, Beeline Holdings, Inc. (BLNE) exchanged the holder's remaining 4,425,102 shares of Series A Convertible Redeemable Preferred Stock for 983,356 shares of common stock, calculated by dividing the stated value by $2.25 per share, resulting in no Series A shares outstanding. This issued fewer shares than the original $1.75 conversion terms, which would have required an additional 280,959 shares. The Company filed a certificate of withdrawal for the Series A designation with the Nevada Secretary of State on March 20, 2026.

• ·Exchange exempt from registration under Section 3(a)(9) of the Securities Act of 1933
• ·Principal executive offices: 188 Valley Street, Suite 225, Providence, RI 02909

20-03-2026

Universal Logistics Holdings, Inc. appointed Ernst & Young LLP as its new independent registered public accounting firm effective March 16, 2026, for the fiscal year ending December 31, 2026. The Audit Committee approved the engagement, and there were no prior consultations with EY on accounting principles, audit opinions, disagreements, or reportable events during fiscal years ended December 31, 2024 and 2025, or through March 16, 2026.

• ·Filing submitted on March 20, 2026.
• ·Registrant incorporated in Nevada, CIK 0001308208, IRS EIN 38-3640097.

20-03-2026

Katapult Holdings, Inc. filed a DEFA14A Definitive Additional Materials proxy statement on March 20, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. No fee was required for the filing, and it was filed by the registrant. The document contains no quantitative financial data, performance metrics, or specific proposals at this time.

• ·Filing categorized as Definitive Additional Materials under Schedule 14A.

20-03-2026

Firdaus Bhathena, Chief Product Technology Officer of Fidelity National Information Services, Inc. (FIS), notified the company of his resignation effective March 20, 2026, on March 18, 2026. No reason for departure or successor announcement was provided in the 8-K filing dated March 20, 2026. This executive change occurs without any disclosed impact on operations or financials.

20-03-2026

On March 16, 2026, Clayton Adams resigned as Chief Executive Officer of CleanCore Solutions, Inc. (ZONE) but will remain on the Board of Directors and serve as General Manager overseeing U.S. and Irish entities, receiving a $500,000 termination payment. The Board appointed Tyler Hassen, 43, with extensive energy and investment experience, as the new CEO effective the same date, with an employment agreement providing a $500,000 annual base salary, $250,000 signing bonus upon a $50M Qualified Financing, $500,000 target annual bonus, and 3.0% equity award. No financial performance impacts were disclosed.

• ·Tyler Hassen employment term: initial 3 years from March 17, 2026, with automatic 1-year renewals unless 30 days' notice.
• ·Tyler Hassen entitled to 20 paid vacation days per year (25 after second anniversary).
• ·Termination Agreement with Clayton Adams includes mutual releases of claims.

20-03-2026

Climb Global Solutions, Inc. filed a Certificate of Amendment to its Restated Certificate of Incorporation, authorizing a total of 40,010,000 shares: 40,000,000 common shares (par value $0.01) and 10,000 preferred shares (par value $0.01). Effective at 4:01 p.m. Eastern Time on March 20, 2026, each outstanding common share will be subdivided into four shares in a 4-for-1 stock split. The amendment was approved solely by the Board of Directors pursuant to DGCL Section 242(d)(1), without stockholder approval.

• ·Previous amendments to Certificate of Incorporation: July 21, 1995 (restated), August 21, 2006, and October 25, 2022.
• ·Par value for both common and preferred stock: $0.01 per share.

20-03-2026

Mountain Lake Acquisition Corp. II (MLAA), a blank check company with no operating history or revenues, filed its 10-K Annual Report covering the period from inception on October 16, 2025, through December 31, 2025, highlighting risks such as limited shareholder evaluation basis and potential negative interest rates on Trust Account investments. The Sponsor or affiliates may provide up to $1.5M in Working Capital Loans to finance transaction costs for a Business Combination, convertible into units at $10.00 per unit. Post-combination, operations may be heavily reliant on foreign assets and revenues, exposing results to economic and political risks in such countries.

• ·Financial statements include Balance Sheet as of December 31, 2025, and Statements of Operations, Changes in Shareholder’s Deficit, and Cash Flows for the period October 16, 2025 (inception) through December 31, 2025.
• ·Report of Independent Registered Public Accounting Firm (PCAOB ID Number 100).

20-03-2026

Eli Lilly and Company (LLY) filed a DEFA14A Definitive Additional Proxy Materials on March 20, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as definitive additional materials rather than preliminary or confidential. No specific proposals, financial data, or substantive proxy details are provided in the filing header.

• ·Filing categorized as Definitive Additional Materials (not Preliminary Proxy Statement or Soliciting Material under §240.14a-12)

20-03-2026

KORE Group Holdings, Inc. entered into additional Rollover, Voting and Support Agreements on March 17, 2026, with Dotmar Investments Limited (847,293 shares), Richard Burston (169,948 shares), and Terrdian Holdings Inc. (1,163,205 shares), committing them to vote in favor of the pending merger with KONA Parent, L.P. and roll over their shares. Under the February 26, 2026 Merger Agreement, remaining shareholders will receive $9.25 per share in cash upon closing, subject to conditions. Parent may enter further rollover agreements for up to 2.5 million as-converted shares within 15 business days of the Merger Agreement.

• ·Merger Agreement dated February 26, 2026
• ·Rollover Agreements dated March 17, 2026
• ·Filing signed March 20, 2026

20-03-2026

Penske Automotive Group, Inc. filed a DEFA14A Definitive Additional Proxy Statement on March 20, 2026, marked as filed by the registrant with no fee required. The document is categorized as Definitive Additional Materials under Schedule 14A. No specific proposals, financial data, or substantive details are included in the provided filing excerpt.

• ·Filing type: DEFA14A (Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934)
• ·Check box: Definitive Additional Materials

20-03-2026

Core Molding Technologies, Inc. (CMT) furnished an investor presentation under Item 7.01 Regulation FD Disclosure, to be used by CEO David Duvall, EVP and CFO Alex Panda, and executive team in conversations with investors and analysts. The slides are attached as Exhibit 99.1 and available on the company's website at www.coremt.com. The information is not deemed filed for liability purposes.

20-03-2026

Constellation Energy Corporation (CEG Parent) and Constellation Energy Generation, LLC completed the acquisition of Calpine Corporation on January 7, 2026, pursuant to the Merger Agreement dated January 10, 2025, converting Calpine into Calpine LLC, an indirect wholly-owned subsidiary of Constellation. The filing includes Calpine's audited consolidated financial statements as of December 31, 2025 and 2024, and for the years ended December 31, 2025, 2024, and 2023 (Exhibit 99.1), as well as unaudited pro forma condensed combined financial statements of CEG Parent and Constellation as of and for the year ended December 31, 2025 (Exhibit 99.2). No specific financial metrics or performance comparisons are disclosed in the filing narrative.

• ·Merger Agreement dated January 10, 2025
• ·Audited financial statements prepared with consents from Deloitte & Touche LLP (23.1) and PricewaterhouseCoopers LLP (23.2)

20-03-2026

Relmada Therapeutics reported positive 12-month Phase 2 data for NDV-01 in NMIBC, showing 95% complete response rate at any time and 76% at 12 months (80%/94% in BCG-unresponsive), with no disease progression or serious adverse events, and plans to initiate Phase 3 RESCUE program mid-2026 following FDA alignment. The company completed a $160M oversubscribed PIPE financing in March 2026, boosting cash to fund operations through 2029. Full-year 2025 net loss improved to $57.4M from $80.0M in 2024 with lower R&D and G&A expenses and reduced cash burn, however Q4 2025 net loss widened slightly to $19.9M from $18.6M driven by higher G&A costs.

• ·No ≥ Grade 3 treatment-related adverse events or treatment-related discontinuations in NDV-01 Phase 2 study.
• ·Estimated ~75,000 US patients/year with intermediate-risk NMIBC; ~5,000 with 2L BCG-unresponsive NMIBC with CIS.
• ·Cash runway expected through 2029 including Phase 3 NDV-01 completion.

20-03-2026

On March 20, 2026, Aeluma, Inc. entered into a Sales Agreement with Roth Capital Partners, LLC (as representative of the agents), Craig-Hallum Capital Group LLC, Northland Securities, Inc., and The Benchmark Company, LLC, enabling the company to offer and sell up to $50 million of its common stock ($0.0001 par value per share) through an at-the-market offering on Nasdaq Capital Market at prevailing market prices. Neither the company nor the agents are obligated to sell or purchase any shares, and the agreement includes mutual indemnification provisions and can be terminated by either party upon 5 business days' prior written notice. The offering is pursuant to the company's effective shelf registration statement on Form S-3 (No. 333-289135, effective August 8, 2025).

• ·Sales effected via ordinary brokers’ transactions at market prices or as otherwise agreed; no principal purchases required.
• ·Prospectus supplement filed immediately prior to this 8-K.
• ·Agreement filed as Exhibit 1.1; legal opinion as Exhibit 5.1.

20-03-2026

Artelo Biosciences, Inc. (ARTL) filed an S-1 registration statement on March 20, 2026, for a public offering of common stock and pre-funded warrants through placement agent Craft Capital Management LLC, with 8.0% fees and warrants equal to 8.0% of securities sold. Interim Phase 2a CAReS trial results for ART27.13 showed compelling efficacy with mean body weight gain of 6.38% (vs -5.42% placebo loss) and lean body mass increase of +4.23% (vs -3.15% placebo) in 18 evaluable cancer anorexia patients, with a favorable safety profile among 32 enrolled participants. ART26.12 Phase 1 SAD study in 49 healthy subjects reported no drug-related adverse events and dose-dependent pharmacokinetics.

• ·ART27.13 dose escalation approved up to 1,300 micrograms; max weight gain 18.5% (ART27.13) vs 0.4% (placebo); max weight loss -3.0% (ART27.13) vs -17.4% (placebo).
• ·ART12.11 composition of matter patent enforceable until December 10, 2038.
• ·ART26.12 IND cleared by FDA in July 2024; Phase 1 results announced June 2025.
• ·CAReS trial: first patient dosed April 2021; Phase 1b completed Q1 2023; Phase 2a initiated April 2023; interim announced September 3, 2025.

20-03-2026

West Enclave Merger Corp., a Cayman Islands blank check company incorporated on December 9, 2025, filed an S-1/A registration statement on March 20, 2026, for an IPO of 10,000,000 units at $10.00 each, targeting gross proceeds of $100M ($98M net before expenses), with $100.25M to be deposited in trust (or $115.29M if over-allotment exercised). The SPAC plans to pursue a business combination within 21 months of closing, focusing on high-quality businesses in Latin America or U.S. operations benefiting from the region, accompanied by private units and a $250K EBC loan. No operational revenues have been generated to date, and investing involves high risks as noted in the Risk Factors section.

• ·Over-allotment option for 1,500,000 additional units.
• ·Business combination must complete within 21 months from offering closing or public shares redeemable.
• ·Company is an emerging growth company with reduced reporting requirements.
• ·No revenues generated to date; efforts limited to organizational activities and offering.

20-03-2026

Faraday Future Intelligent Electric Inc. received a Nasdaq notice on March 20, 2026, for failing to maintain a minimum $1.00 bid price for its Class A common stock (FFAI) over 30 consecutive trading days from February 5 to March 19, 2026, violating Listing Rule 5550(a)(2). The company has 180 calendar days until September 16, 2026, to regain compliance by sustaining a $1.00 closing bid price for at least 10 consecutive trading days, or risk delisting, though a second compliance period or reverse stock split could be options. Continued trading on Nasdaq Capital Market is allowed during this period, but a bid price of $0.10 or less for 10 consecutive days would trigger immediate delisting proceedings.

• ·Compliance period allows up to 20 business days at Nasdaq's discretion instead of 10 for bid price regainment.
• ·Second 180-day period possible if company meets market value of publicly held shares and other Nasdaq Capital Market initial listing standards (except bid price).

20-03-2026

Perfect Moment Ltd. (PMNT) entered into a Second Further Amended and Restated Promissory Note with Chairman Max Gottschalk on March 20, 2026, extending the maturity of the $3.39M unsecured loan (originally due November 8, 2025) from March 23, 2026, to March 31, 2026, following multiple prior extensions. This is part of total outstanding loans of $5.09M from Gottschalk, including a separate $1.7M note due August 18, 2030. While the extension provides short-term liquidity relief, the repeated amendments highlight ongoing working capital constraints and reliance on insider funding.

• ·Loans bear interest at 12% per annum, with interest payable monthly.
• ·Note #1 originally issued August 26, 2025; prior maturities extended from November 8, 2025 to March 9, 2026, then March 23, 2026.

20-03-2026

PureCycle Technologies, Inc. filed an 8-K on March 20, 2026, disclosing under Regulation FD its participation in the Annual ROTH Conference on March 23, 2026, with a webcast link provided. Exhibit 99.1 includes a press release dated March 20, 2026. The filing was signed by Donald Carpenter, Chief Financial Officer.

• ·Securities registered: Common Stock (PCT), Warrants (PCTTW exercisable at $11.50 per share), Units (PCTTU each consisting of one share of common stock and three quarters of one warrant).

20-03-2026

Invesco Mortgage Capital Inc. filed its 2026 Proxy Statement for the Annual Meeting, seeking stockholder approval for the election of six director nominees (Robert L. Fleshman, Katharine W. Kelley, Stephanie J. Larosiliere, Don H. Liu, W. Wesley McMullan, and Robert B. Waldner) to serve until the 2027 Annual Meeting, following the planned reduction of the Board from eight to seven members due to Carolyn Gibbs' retirement on March 31, 2026, and Carolyn Handlon not seeking re-election. Additional proposals include an advisory vote to approve executive compensation and ratification of PricewaterhouseCoopers LLP as independent auditors for the year ending December 31, 2026, with the Board unanimously recommending a FOR vote on all items. No financial performance metrics are disclosed in the filing.

• ·Don H. Liu appointed Board Chair on November 4, 2025.
• ·Robert L. Fleshman appointed director on November 8, 2024, and Audit Committee Chair effective January 1, 2026.
• ·Director election requires majority of votes cast; incumbent nominees not elected must submit resignation for Board consideration.
• ·Filing references Annual Report on Form 10-K for year ended December 31, 2025.

20-03-2026

Helios Technologies, Inc. hosted an Investor Day on March 20, 2026, presenting the 'Igniting the Momentum: The CORE 2030 Strategy' led by Sean Bagan (President & CEO) and Jeremy Evans (EVP & CFO), outlining plans for innovation, market share growth, market expansion, and 2030 financial targets. The company also announced a $0.12 per share cash dividend, payable April 27, 2026, to shareholders of record as of April 13, 2026. No comparative financial performance data was disclosed.

• ·Live webcast available at https://www.heliostechnologies.com/investors
• ·Replay of presentations and slides to be available following the event

20-03-2026

The United States Commodity Index Funds Trust filed an 8-K on March 20, 2026, under Items 7.01 and 9.01, disclosing the audited Statements of Financial Condition of its sponsor, United States Commodity Funds LLC (USCF), as of December 31, 2025 and 2024, attached as Exhibit 99.1. This information is furnished pursuant to Regulation FD and is not deemed 'filed' for liability purposes under the Exchange Act. No specific financial metrics or changes between periods are detailed in the filing body.

20-03-2026

United States 12 Month Natural Gas Fund, LP (UNL) filed an 8-K on March 20, 2026, under Items 7.01 and 9.01, disclosing audited Statements of Financial Condition for its general partner, United States Commodity Funds LLC (USCF), as of December 31, 2025 and 2024 (Exhibit 99.1). The information is furnished pursuant to Regulation FD and explicitly not deemed 'filed' for purposes of Section 18 of the Exchange Act or liabilities thereunder. No specific financial metrics or period-over-period changes are detailed in the filing body.

• ·Commission File Number: 001-34535
• ·I.R.S. Employer Identification No.: 26-0431733
• ·Principal executive offices: 1850 Mt. Diablo Boulevard, Suite 640, Walnut Creek, California 94596
• ·Registrant’s telephone number: (510) 522-9600

20-03-2026

United States 12 Month Oil Fund, LP (USL) filed an 8-K on March 20, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, furnishing audited Statements of Financial Condition of its general partner, United States Commodity Funds LLC (USCF), as of December 31, 2025 and 2024 (attached as Exhibit 99.1). No specific financial metrics, performance changes, or period-over-period comparisons are provided in the filing body.

• ·Filing includes standard registrant details: Delaware incorporation, Commission File Number 001-33859, I.R.S. Employer Identification No. 26-0431897, principal offices at 1850 Mt. Diablo Boulevard, Suite 640, Walnut Creek, California 94596, telephone (510) 522-9600.
• ·Information in Item 7.01 and Exhibit 99.1 is not 'filed' under Section 18 of the Exchange Act or subject to liabilities therein.

20-03-2026

Telix Pharmaceuticals Limited filed Amendment No. 1 to its Form 20-F Annual Report for the fiscal year ended December 31, 2025, on March 20, 2026, to correct hyperlinks for Exhibits 4.17, 4.18, 8.1, 11.1, 12.1, 12.2, 13.1, and 13.2 from the original filing on February 20, 2026. No financial statements or substantive disclosures were amended or restated. The company reported 338,777,049 ordinary shares outstanding as of December 31, 2025.

• ·Classified as a large accelerated filer and well-known seasoned issuer.
• ·Prepares financial statements under International Financial Reporting Standards (IFRS).
• ·Securities: American Depositary Shares (TLX) listed on Nasdaq Global Select Market; ordinary shares not listed for trading.

20-03-2026

TELA Bio, Inc. received a Nasdaq deficiency notice on March 17, 2026, stating that its common stock (TELA) closing bid price was below the $1.00 minimum for 30 consecutive business days, violating Listing Rule 5450(a)(1). The company has 180 calendar days until September 14, 2026, to regain compliance by closing at $1.00 or higher for 10 consecutive business days, with trading continuing uninterrupted for now and a possible second 180-day period if transferred to Nasdaq Capital Market. The company intends to monitor and address the issue, but success is not assured.

• ·Nasdaq deficiency letter issued by Listing Qualifications Department Staff.
• ·Company headquartered at 1 Great Valley Parkway, Suite 24, Malvern, Pennsylvania 19355.
• ·Trading symbol: TELA.